Last updated: August 2, 2026
Winstrol is the former brand name for stanozolol, an anabolic steroid used historically in human medicine and veterinary products. Its commercial trajectory is defined by mature chemistry, long-expired core intellectual property, limited current branded availability, controlled-substance regulation, and demand that has shifted from conventional prescriptions toward specialty, veterinary, compounding, and illicit performance-enhancement channels. No reliable public source reports standalone Winstrol revenue, current global sales, or a separately disclosed manufacturer profit stream.
What is Winstrol and who owns the drug?
Winstrol is a brand associated with stanozolol, a synthetic derivative of dihydrotestosterone. The compound has anabolic and androgenic activity and has been used in medical treatment of hereditary angioedema and other historical indications. Stanozolol is also known as Stanazol, Stromba, and by multiple country-specific generic names.
The original commercial product was associated with Winthrop Laboratories and later corporate successors. Ownership and marketing rights varied by country and product type. The brand should not be treated as a single globally controlled asset because human tablets, injectable products, and veterinary formulations have had different sponsors and regulatory histories.
| Item |
Assessment |
| Active ingredient |
Stanozolol |
| Brand |
Winstrol |
| Drug class |
Anabolic androgenic steroid |
| Human dosage forms |
Historically oral tablets and injectable products |
| Veterinary brand |
Winstrol-V and country-specific equivalents |
| U.S. controlled-substance status |
Schedule III under the Controlled Substances Act |
| Biologic status |
Not a biologic; biosimilar pathway does not apply |
| Current branded U.S. commercial position |
No meaningful active branded franchise is publicly evident |
| Core patent position |
Mature and generally expired |
| Standalone revenue disclosure |
Not publicly available |
The U.S. Food and Drug Administration identifies stanozolol as an approved or historically approved drug substance, but current commercial availability depends on the specific sponsor, dosage form, and market. Product availability is not equivalent to regulatory approval. A pharmacy, compounding facility, or foreign supplier may distribute stanozolol without indicating that the original Winstrol brand remains actively marketed in the United States.
What is the FDA regulatory status of Winstrol?
Winstrol’s regulatory status is fragmented because the brand has a long product history and multiple formulations. The relevant distinction is between historical FDA approval, current marketing, and lawful distribution.
Stanozolol has been subject to FDA regulation as a prescription anabolic steroid. The drug is also regulated under the Anabolic Steroids Control Act and is listed by the Drug Enforcement Administration as a Schedule III controlled substance.[1]
The primary regulatory factors are:
- prescription-only distribution;
- controlled-substance recordkeeping;
- restrictions on manufacturing and dispensing;
- anti-doping rules in professional and amateur sports;
- veterinary drug requirements for animal products;
- manufacturing compliance for active pharmaceutical ingredients and finished dosage forms.
The FDA does not treat Winstrol as a current mass-market branded product comparable to an actively promoted cardiovascular, oncology, or diabetes drug. Current U.S. commercial activity is more likely to involve generic stanozolol, pharmacy compounding, imported products, veterinary products, or illegal sales than a conventional branded prescription franchise.
Is Winstrol still marketed in the United States?
There is no robust public evidence of a large-scale, actively promoted U.S. Winstrol brand business. Historical Winstrol products may remain visible in medical references, online catalogs, or international markets after commercial discontinuation.
The FDA’s Drugs@FDA and Orange Book databases should be read at the application and product level. A discontinued brand, an inactive application, or an approved product without current commercial distribution does not create a viable branded revenue stream.[2,3]
When does Winstrol lose exclusivity?
Winstrol’s core exclusivity expired decades ago. Stanozolol was introduced in the 1960s, placing its foundational composition and manufacturing rights well outside the modern patent term for pharmaceutical products.
| Exclusivity category |
Current position |
| Original compound protection |
Expired |
| Original formulation protection |
Expired or commercially irrelevant |
| New chemical entity exclusivity |
Not applicable to current market |
| Orphan exclusivity |
No active modern orphan franchise identified |
| Data exclusivity |
Expired |
| Pediatric exclusivity |
No active period |
| Biosimilar exclusivity |
Not applicable |
| Current branded patent moat |
None of commercial significance identified |
No active patent estate comparable to a modern branded pharmaceutical franchise is publicly associated with the original Winstrol product. Any surviving patents would likely concern later formulation, manufacturing, veterinary, or delivery innovations rather than the basic stanozolol molecule.
What patents protect Winstrol and stanozolol?
The economically relevant patent protection for stanozolol has ended. The compound’s commercial life began before the current 20-year-from-filing patent framework became the dominant basis for pharmaceutical exclusivity in the United States.
Potential historical or later patent categories include:
- composition-of-matter claims covering stanozolol or related steroid structures;
- synthetic routes and intermediate compounds;
- tablet formulations;
- injectable suspensions or solutions;
- veterinary formulations;
- therapeutic use claims;
- packaging and manufacturing-process claims.
These categories do not create a meaningful present-day barrier to generic development. A company seeking to commercialize stanozolol would face regulatory, controlled-substance, supply-chain, and market-demand issues rather than a basic molecule patent barrier.
Are there Orange Book patents for Winstrol?
No currently material Orange Book patent position is publicly associated with Winstrol as a commercially active U.S. brand. An Orange Book entry must be evaluated against the specific reference listed drug and active application. Historical listing, discontinued status, or an absence of current marketing does not support a current patent-based exclusivity claim.
A generic applicant could still face regulatory questions involving the reference product, dosage form, labeling, or discontinued-drug determination. Those issues are distinct from patent infringement risk.
Are there Paragraph IV challenges to Winstrol?
A commercially significant current Paragraph IV campaign involving Winstrol has not been identified in the publicly visible patent-litigation record.
Paragraph IV litigation generally requires an abbreviated new drug application referencing a listed drug with relevant Orange Book patents. Winstrol’s limited current branded presence reduces the likelihood of a conventional branded-versus-generic litigation cycle.
The more likely regulatory path for a stanozolol manufacturer is:
- an abbreviated new drug application, if a suitable reference product is available;
- a suitability petition or related FDA pathway, if the proposed dosage form differs;
- a manufacturing or compounding route subject to applicable rules;
- veterinary approval for animal products;
- foreign-market authorization where the product remains registered.
How strong is the Winstrol patent estate?
The Winstrol patent estate is weak from a present-day commercial perspective.
| Patent-strength factor |
Rating |
Reason |
| Core molecule protection |
Low |
Historical protection has expired |
| Formulation protection |
Low |
No current high-value formulation moat identified |
| Method-of-use protection |
Low |
Longstanding medical uses are mature |
| Manufacturing protection |
Low to moderate |
Process know-how may affect cost but is unlikely to block entry |
| Regulatory exclusivity |
Low |
No active modern exclusivity period identified |
| Litigation leverage |
Low |
Limited evidence of a current branded product dispute |
| Supply-chain control |
Moderate |
Controlled-substance sourcing can constrain compliant suppliers |
| Commercial differentiation |
Low |
Generic substitution and nonmedical demand dominate |
The strongest barriers are operational rather than intellectual-property based. These include controlled-substance quotas, API sourcing, testing, serialization, pharmacovigilance, facility registration, and the risk of enforcement against noncompliant distributors.
What formulations are protected by Winstrol?
Historical Winstrol products included oral tablets and injectable formulations. Veterinary products have been sold in dosage forms distinct from human products.
No current formulation patent appears to create a durable barrier across the stanozolol market. A sponsor could still obtain protection for a genuinely novel delivery system, such as a long-acting injectable, transdermal system, or abuse-deterrent formulation. That protection would cover the new formulation rather than the ordinary stanozolol molecule.
The commercial case for a new formulation is limited. Development would require clinical justification, controlled-substance compliance, manufacturing validation, and a clear medical need. The established human indication base is narrow compared with large endocrine or chronic-disease markets.
How does Winstrol compare with competing anabolic steroids?
Winstrol competes in several different markets, and the competitive set changes by channel.
| Product or compound |
Primary market |
Commercial position |
| Stanozolol/Winstrol |
Historical human use, veterinary use, illicit performance enhancement |
Mature, fragmented |
| Oxandrolone/ Anavar |
Medical and performance-enhancement markets |
Stronger historical brand recognition and broader specialty demand |
| Testosterone products |
Approved hormone replacement and performance-enhancement markets |
Much larger regulated market |
| Nandrolone |
Medical history and performance-enhancement markets |
Generic and fragmented |
| Methandienone/Dianabol |
Primarily non-U.S. and illicit markets |
Limited regulated U.S. relevance |
| Erythropoietin products |
Anemia and performance abuse |
Biologic category with different regulation and economics |
Testosterone has the largest legitimate commercial infrastructure because it has established replacement-therapy indications and multiple approved delivery systems. Oxandrolone has historically held more recognizable specialty value in some medical and performance-enhancement segments. Winstrol’s commercial identity is narrower and more exposed to regulatory enforcement.
What is the market size and revenue trajectory for Winstrol?
No audited standalone Winstrol revenue series is publicly available. The brand is not generally disclosed as a separate reporting segment by major pharmaceutical companies, and stanozolol sales are not reported as a transparent global market category.
The likely revenue trajectory is:
| Period |
Commercial condition |
Revenue direction |
| 1960s-1980s |
Branded prescription and veterinary expansion |
Growth |
| 1990s |
Generic competition and increasing safety scrutiny |
Decline in branded value |
| 2000s |
Reduced mainstream human use and product discontinuations |
Continued decline |
| 2010s |
Fragmented generic, veterinary, compounding, and illicit demand |
Flat or fragmented |
| 2020s |
Controlled-substance enforcement and online-market disruption |
No visible branded recovery |
The relevant financial metric is not historical peak revenue. It is the residual addressable market available to a compliant manufacturer. That market is likely small relative to mainstream pharmaceutical categories and may be divided among:
- legitimate veterinary demand;
- limited physician-directed human use;
- compounding demand where legally permitted;
- international generic sales;
- illegal performance-enhancement supply.
Illicit sales should not be treated as pharmaceutical revenue. They create demand signals but do not provide dependable, auditable earnings for a regulated manufacturer.
What factors drive Winstrol market dynamics?
Medical demand
Medical demand is constrained by the availability of alternative therapies, narrow indications, adverse-effect concerns, and changing clinical practice. Stanozolol’s risk profile includes hepatic toxicity, lipid changes, androgenic effects, virilization, and suppression of endogenous hormone production. LiverTox identifies anabolic steroids, including 17-alpha-alkylated compounds, as relevant to drug-induced liver injury risk.[4]
Veterinary demand
Veterinary products have historically provided a separate commercial channel. That market is constrained by animal-use restrictions, residue controls, veterinary prescribing rules, and the risk that a human product is unlawfully diverted.
Sports and bodybuilding demand
Stanozolol is prohibited by the World Anti-Doping Agency at all times, both in and out of competition.[5] Sports-related demand supports illicit-market visibility but increases enforcement risk and reduces the attractiveness of a mainstream branded strategy.
Supply and manufacturing
Stanozolol manufacturing requires controlled handling, qualified API suppliers, analytical testing, and compliance with current good manufacturing practices. A manufacturer may also face quota and registration requirements under the DEA framework.
Online distribution
Online channels have increased product visibility but have not created a stable pharmaceutical market. Counterfeit products, inaccurate labeling, contamination, and unlawful importation are material risks. FDA enforcement actions against unapproved or misbranded steroid products can disrupt supply without affecting legitimate generic demand.
What generic entry risks exist for Winstrol?
Generic entry risk is high because the active ingredient is old, the molecule is chemically defined, and meaningful patent protection has expired. The main risks to a generic entrant are commercial and regulatory:
- absence of a large active reference-brand market;
- uncertainty over the size of legitimate demand;
- controlled-substance manufacturing requirements;
- API availability;
- low pricing and limited reimbursement;
- competition from compounding or foreign supply;
- enforcement against online and unapproved sellers;
- possible discontinuation of low-volume products.
A generic entrant could obtain technical approval yet fail to build a profitable business. The market may support one or a few compliant suppliers without supporting significant promotional investment.
What patent litigation and settlements affect Winstrol?
No major current U.S. patent litigation or settlement agreement involving the Winstrol brand has been identified as a material driver of market access. The absence of litigation is consistent with the product’s mature patent position and limited active branded commercialization.
Any due diligence should distinguish among:
- patent suits involving stanozolol itself;
- enforcement actions involving illegal steroid distribution;
- trademark disputes over the Winstrol name;
- FDA actions concerning unapproved products;
- veterinary regulatory actions;
- cases involving unrelated anabolic steroids.
These proceedings have different implications. Regulatory enforcement can affect supply without extending patent exclusivity.
Are licensing deals relevant to Winstrol?
No major current licensing transaction involving the Winstrol brand or stanozolol has been publicly disclosed as a meaningful pharmaceutical revenue driver. Historical corporate transfers may have moved product rights among pharmaceutical companies, but those arrangements do not establish a current high-value asset.
A modern licensing opportunity would likely involve one of three assets:
- rights to a registered veterinary product in a specific country;
- a compliant generic formulation;
- a new delivery system or therapeutic use.
The base stanozolol molecule alone is unlikely to command material licensing economics.
What is the geographic coverage of Winstrol?
Winstrol and stanozolol have had uneven geographic availability.
- United States: controlled prescription status, limited branded presence, generic and veterinary considerations.
- Europe: country-specific authorization and availability; the original brand may be absent or discontinued.
- Latin America: broader historical visibility, but product quality and regulatory status vary.
- Asia: availability differs by jurisdiction and may include veterinary or illicit channels.
- Australia and other regulated markets: anabolic-steroid controls and prescription restrictions apply.
A company commercializing stanozolol would need country-by-country confirmation of registration, controlled-substance status, manufacturing authorization, labeling, and reimbursement. Global brand recognition does not establish global market access.
Key Takeaways
- Winstrol is the legacy brand associated with stanozolol, an anabolic androgenic steroid.
- The core molecule and historical exclusivity have expired.
- No material current patent moat, active branded franchise, or major Paragraph IV campaign is evident.
- Winstrol is not a biologic, so biosimilar competition is irrelevant.
- No reliable standalone revenue or current global market-size figure is publicly reported.
- Legitimate demand is fragmented across limited human use, veterinary products, generics, and compounding.
- Illicit performance-enhancement demand increases visibility but does not represent dependable pharmaceutical revenue.
- The main barriers are controlled-substance compliance, API supply, manufacturing quality, enforcement, and weak market economics.
- A generic entrant faces high technical entry feasibility but uncertain commercial returns.
- New formulation or delivery-system rights could create value, but the legacy tablet and injectable products have little defensible exclusivity.
FAQs
Is Winstrol still an FDA-approved drug?
Stanozolol has a historical FDA approval record, but the commercial status of a particular Winstrol product depends on its sponsor, dosage form, and current marketing status. Historical approval does not mean the branded product is actively sold.
Can a pharmaceutical company launch generic stanozolol?
Generic launch may be possible subject to FDA requirements, reference-product availability, controlled-substance rules, and manufacturing compliance. Commercial viability is a separate question because the legitimate market is limited.
Does Winstrol have an active U.S. patent?
No commercially significant active patent estate is publicly associated with the original Winstrol product. Any later patent would need to be evaluated by formulation, use, process, and jurisdiction.
Is Winstrol covered by Medicare or commercial insurance?
Coverage depends on the specific stanozolol product, indication, payer policy, and formulary. A discontinued or unavailable branded product does not create a stable reimbursement market.
Is stanozolol a biosimilar opportunity?
No. Stanozolol is a small-molecule chemical drug. Competition would involve generic-drug pathways, not biosimilar approval.
References
- U.S. Drug Enforcement Administration. (2024). Drug fact sheet: Anabolic steroids. https://www.dea.gov
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
- National Institute of Diabetes and Digestive and Kidney Diseases. (2020). Androgenic steroids. In LiverTox: Clinical and research information on drug-induced liver injury. https://www.ncbi.nlm.nih.gov/books/NBK548931/
- World Anti-Doping Agency. (2024). The 2024 prohibited list. https://www.wada-ama.org/sites/default/files/2023-09/2024list_en_final_22_september_2023.pdf
